Re: NVS webcast/ARRY Another upcoming webcast of interest is NVS’ annual oncology presentation tomorrow at 8am ET: www.novartis.com/investors/presentations-events/index.shtml#2010-12-14-oncologyI'm anxious to hear to what extent NVS discusses its development plans for ARRY-162, the MEK inhibitor it licensed from ARRY.